ICU SeaStar Medical
- 0.3547
- -0.0053-1.47%
- 0.3481
- -0.0066-1.86%
SeaStar Medical News
SeaStar MEdical Holdings Publishes Manuscript On Multiorgan Failure Patients Treated With Selective Cytopheretic Device
SCD's ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct
SeaStar Medical Holding Q1 2024 Adj EPS $(0.19) Misses $(0.15) Estimate
SeaStar Medical Holding (NASDAQ:ICU) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.15) by 26.67 percent.
10-Q: Quarterly report
SeaStar Medical Announces $3.6M NIH Grant Award To Study Selective Cytopheretic Device In Adult Patients With Severe Chronic Heart Failure
SeaStar Medical Announces $3.6M NIH Grant Award To Study Selective Cytopheretic Device In Adult Patients With Severe Chronic Heart Failure
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session.The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with t
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alcoa Corporation (NYSE:AA) rose sharply in today's pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of
SeaStar Medical Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results.
SeaStar Medical Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results.
SeaStar Medical Holding 2023 Loss/Shr $1.21
SeaStar Medical Holding 2023 Loss/Shr $1.21
SeaStar Medical Holding Q4 EPS $(0.19) Misses $(0.13) Estimate
SeaStar Medical Holding (NASDAQ:ICU) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 93.73 percent increase over losse
SeaStar Medical Holding (ICU.US): The 2023 Q4 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.19 dollars, previous value was -3.03 dollars, and expected value was -0.13 dollars.
SeaStar Medical Holding (ICU.US): The 2023 Q4 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.19 dollars, previous value was -3.03 dollars, and expected value was -0.13 dollars.
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on
SeaStar Medical Holding: Restatement Is Not Expected to Have a Material Impact on Business Ops or Cash Position, but Rather Is Related to Reporting of Non-Cash Acctg Items >ICU
SeaStar Medical Holding: Restatement Is Not Expected to Have a Material Impact on Business Ops or Cash Position, but Rather Is Related to Reporting of Non-Cash Acctg Items >ICU
SeaStar Medical Holding: Restatement Will Affect Acctg Treatment and Classification of Certain Outstanding Warrants and the Prepaid Forward Purchase Arrangement That Was Terminated in June 2023 >ICU
SeaStar Medical Holding: Restatement Will Affect Acctg Treatment and Classification of Certain Outstanding Warrants and the Prepaid Forward Purchase Arrangement That Was Terminated in June 2023 >ICU
SeaStar Medical to Restate Financials for Fiscal Year Ended Dec. 31, 2022, and for Interim Periods Ended March 31, 2023, June 30, 2023 and Sept. 30, 2023
SeaStar Medical to Restate Financials for Fiscal Year Ended Dec. 31, 2022, and for Interim Periods Ended March 31, 2023, June 30, 2023 and Sept. 30, 2023
SeaStar Medical Provides Updates On Enrollment Of Adult Pivotal Clinical Study And Commercial Launch Of Quelimmune, FDA-Approved In Pediatric Patients
Company plans to hold a business update conference call in AprilDENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial stage medical device company d
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to Be Webcast Live at AKI & CRRT 2024
March 13 webcast showcasing Quelimmune scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024 (GLOBE
Peering Into SeaStar Medical Holding's Recent Short Interest
SeaStar Medical Holding's (NYSE:ICU) short percent of float has risen 65.93% since its last report. The company recently reported that it has 2.49 million shares sold short, which is 4.53% of all regu
Manuscript Discussing The Benefit Of SeaStar Medical's Selective Cytopheretic Device In Patients With Heart Failure And Hyperinflammation Published In European Journal Of Heart Failure
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patientsDENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medi
12 Health Care Stocks Moving In Friday's Intraday Session
GainersMaravai LifeSciences (NASDAQ:MRVI) stock increased by 65.5% to $8.46 during Friday's regular session. The company's market cap stands at $1.1 billion. As per the press release, Q4 earnings came
Analysis
Price Target
No Data
